| | |
| Clinical data | |
|---|---|
| Trade names | Iodaque, Hexopaque, Oraltag, others |
| Other names | 5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intrathecal, intravascular, by mouth, intracavital, rectal |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Low |
| Metabolism | Nil |
| Elimination half-life | Variable |
| Excretion | Kidney, unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.060.130 |
| Chemical and physical data | |
| Formula | C19H26I3N3O9 |
| Molar mass | 821.142 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 174 to 180 °C (345 to 356 °F) |
| |
| |
| | |
Iohexol, sold under the trade names Omnipaque and Iodaque among others, is a contrast agent used for X-ray imaging. [3] This includes when visualizing arteries, veins, ventricles of the brain, the urinary system, and joints, as well as during computed tomography (CT scan). [3] It is given by mouth, injection into a vein, or into a body cavity. [4]
Side effects include vomiting, skin flushing, headache, itchiness, kidney problems, and low blood pressure. [3] Less commonly allergic reactions or seizures may occur. [3] Allergies to povidone-iodine or shellfish do not affect the risk of side effects more than other allergies. [5] Use in the later part of pregnancy may cause hypothyroidism in the baby. [6] Iohexol is an iodinated non-ionic radiocontrast agent. [3] It is in the low osmolar family. [7]
Iohexol was approved for medical use in 1985. [8] It is on the World Health Organization's List of Essential Medicines. [9] [4]
The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood. [10] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high. [11]
The most common side effects after intravenous injections are: pain at the site of injection (3%), blurring of vision (2%), nausea (2%), arrhythmia (2%), taste perversion (1%), hypotension (0.7%), and vomiting (0.7%). [12]
It is sold under the brand name Omnipaque. [13] It is also sold as a density gradient medium under the names Accudenz, Histodenz, and Nycodenz. [14] [15]
It is available in various concentrations, from 140 [12] to 350 [16] milligrams of iodine per milliliter. [12] Iohexol can given as intrathecal, intravascular, oral, rectal, intraarticular, or into the body cavity. [12]